drugset

drugset / Trial / NCT01702064

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

NCT01702064 ↗

Phase 1 Completed 11 enrolled H. Lee Moffitt Cancer Center and Research Institute Incyte Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the maximal tolerated dose of Ruxolitinib in combination with nilotinib in patients with chronic myeloid leukemia (CML).

Timeline

Start: 2013-02-21
Primary completion: 2016-10-17
Completion: 2019-01-09

Publications

Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018 Nov;74:89-96. doi: 10.1016/j.leukres.2018.10.002. Epub 2018 Oct 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	5 mg	Oral
Subject	Ruxolitinib	Small molecule	10 mg	Oral
Subject	Ruxolitinib	Small molecule	15 mg	Oral
Background	Nilotinib	Small molecule	300 mg	Oral
Background	Nilotinib	Small molecule	400 mg	Oral

Indications